Insulet (Nasdaq:PODD) today initiated a voluntary medical device correction for specific lots of Omnipod 5 insulin pump pods.

A tear in the tubing may prevent users from getting full insulin doses. So far 18 people have reported serious issues related ...

Insulet estimates that the pods involved in this correction represent approximately 1.5% of annual production globally.

An insulin pump maker is recalling certain pods that can fail to fully infuse insulin in the body. The recall comes after 18 reports of “serious adverse events." ...

Insulet has begun recalling specific lots of its Omnipod 5 insulin pumps in the U.S. | The diabetes tech company said it is ...

Insulet Corp. has identified a manufacturing issue with some of its medical devices that provide automated insulin delivery.

Insulet Corporation (NASDAQ:PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked ...

Insulet (Nasdaq:PODD) shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes.

OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (PODD), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Omnipod 5 is now ...

Insulet, maker of the OmniPod insulin pump, has launched a new tablet app aimed at children. The app, called Toby's T1D Tale, is essentially a virtual story book intended for teaching young children ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

As Americans flock to nearby orchards for festive bouts of autumn apple picking, Insulet is celebrating a particularly bountiful stateside Apple harvest itself. The diabetes devicemaker has earned FDA ...